Cargando…
非小细胞肺癌患者的肿瘤突变负荷异质性研究进展
Programmed death ligand 1 (PD-L1) is a well known biomarker for targeted immunotherapy. However, the relationship between the expression of PD-L1 and the immunotherapy efficacy is not always consistent in different cases. Some patients who are PD-L1 negative still can benefit from immunosuppressive...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105611/ https://www.ncbi.nlm.nih.gov/pubmed/33910278 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.12 |